https://www.fool.com/investing/value/2007/03/19/pfizers-newest-blockbuster.aspx
https://www.fool.com/investing/high-growth/2007/06/12/when-dr-nissen-talks.aspx
https://www.fool.com/investing/value/2006/10/17/bad-news-is-good-news-for-pfizer.aspx
https://www.fool.com/investing/international/2008/01/17/two-sources-of-trouble-for-vytorin.aspx
https://www.fool.com/investing/high-growth/2006/11/07/will-a-10bagger-go-higher.aspx
https://www.fool.com/investing/general/2006/10/31/an-opening-for-plavix.aspx
https://www.fool.com/investing/general/2009/04/06/investing-in-pharma-remember-rule-no-1.aspx
https://www.fool.com/investing/value/2006/12/04/pfizers-cholesteroldrug-hopes-crumble.aspx
https://www.fool.com/investing/value/2007/05/07/buffetts-advice-for-young-investors.aspx
https://www.fool.com/investing/dividends-income/2008/04/02/irrational-exuberance-for-vytorin-and-zetia.aspx
https://www.fool.com/investing/international/2007/07/18/the-worlds-most-valuable-companies.aspx
https://www.fool.com/investing/value/2006/11/08/cvscaremark-a-brobdingnagian-drug-seller.aspx
https://www.fool.com/investing/value/2006/12/11/the-challenges-of-valuing-drug-companies.aspx
https://www.fool.com/investing/general/2006/10/23/are-pacemaker-prices-heading-for-a-fall.aspx
https://www.fool.com/investing/value/2006/09/27/a-drugprice-avalanche.aspx
https://www.fool.com/investing/value/2008/05/19/berkshire-hathaways-next-ceo.aspx
https://www.fool.com/investing/dividends-income/2007/03/29/stents-on-trial.aspx
https://www.fool.com/investing/value/2007/01/22/will-medicare-negotiate-with-drug-companies.aspx
